Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Aberrant localization of the neuronal class III beta-tubulin in astrocytomas - A marker for anaplastic potential
Autore:
Katsetos, CD; Del Valle, L; Geddes, JF; Assimakopoulou, M; Legido, A; Boyd, JC; Balin, B; Parikh, NA; Maraziotis, T; de Chadarevian, JP; Varakis, JN; Matsas, R; Spano, A; Frankfurter, A; Herman, MM; Khalili, K;
Indirizzi:
St Christophers Hosp Children, Dept Pediat, Philadelphia, PA 19134 USA St Christophers Hosp Children Philadelphia PA USA 19134 hia, PA 19134 USA St Christophers Hosp Children, Dept Pathol & Lab Med, Philadelphia, PA 19134 USA St Christophers Hosp Children Philadelphia PA USA 19134 hia, PA 19134 USA Med Coll Penn & Hahnemann Univ, Sch Med, Dept Pediat, Philadelphia, PA 19102 USA Med Coll Penn & Hahnemann Univ Philadelphia PA USA 19102 ia, PA 19102 USA Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia,PA 19122 USA Temple Univ Philadelphia PA USA 19122 anc Biol, Philadelphia,PA 19122 USA Univ London, Dept Histopathol & Morbid Anat, London, England Univ London London England t Histopathol & Morbid Anat, London, England Univ Patras, Sch Med, Dept Anat, GR-26110 Patras, Greece Univ Patras Patras Greece GR-26110 d, Dept Anat, GR-26110 Patras, Greece Univ Patras, Sch Med, Dept Neurosurg, GR-26110 Patras, Greece Univ PatrasPatras Greece GR-26110 pt Neurosurg, GR-26110 Patras, Greece Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA Univ Virginia Charlottesville VA USA 22903 Charlottesville, VA 22903 USA Univ Virginia, Dept Biol, Charlottesville, VA 22903 USA Univ Virginia Charlottesville VA USA 22903 Charlottesville, VA 22903 USA Philadelphia Coll Osteopath Med, Philadelphia, PA USA Philadelphia Coll Osteopath Med Philadelphia PA USA Philadelphia, PA USA Hellenic Pasteur Inst, Dept Biochem, Athens, Greece Hellenic Pasteur InstAthens Greece Inst, Dept Biochem, Athens, Greece NIMH, Clin Brain Disorders Branch, Neuropathol Sect, NIH, Bethesda, MD 20892 USA NIMH Bethesda MD USA 20892 Neuropathol Sect, NIH, Bethesda, MD 20892 USA
Titolo Testata:
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
fascicolo: 5, volume: 125, anno: 2001,
pagine: 613 - 624
SICI:
0003-9985(200105)125:5<613:ALOTNC>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROSTATE CARCINOMA-CELLS; MICROTUBULE-ASSOCIATED PROTEIN-2; RECURRENT MALIGNANT GLIOMA; IMMUNOHISTOCHEMICAL CHARACTERIZATION; COMPARATIVE IMMUNOBLOT; POSTTRANSLATIONAL MODIFICATION; PLEOMORPHIC XANTHOASTROCYTOMA; CEREBRAL HEMISPHERES; SUBVENTRICULAR ZONE; BETA(III) ISOTYPE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
78
Recensione:
Indirizzi per estratti:
Indirizzo: Katsetos, CD St Christophers Hosp Children, Neurol Sect, Res Labs, Eire Ave & Front St,Philadelphia, PA 19134 USA St Christophers Hosp Children Eire Ave & Front St Philadelphia PA USA 19134
Citazione:
C.D. Katsetos et al., "Aberrant localization of the neuronal class III beta-tubulin in astrocytomas - A marker for anaplastic potential", ARCH PATH L, 125(5), 2001, pp. 613-624

Abstract

Background.-The class III beta -tubulin isotype (beta III) is widely regarded as a neuronal marker in development and neoplasia. In previous work, wehave shown that the expression of beta III in neuronal/neuroblastic tumorsis differentiation dependent. In contrast, the aberrant localization of this isotype in certain nonneuronal neoplasms, such as epithelial neuroendocrine lung tumors, is associated with anaplastic potential. Objective.-To test the generality of this observation, we investigated theimmunoreactivity profile of beta III in astrocytomas. Design,Sixty archival, surgically excised astrocytomas (8 pilocytic astrocytomas, WHO grade 1; 18 diffuse fibrillary astrocytomas, WHO grade 2; 4 anaplastic astrocytomas, WHO grade 3; and 30 glioblastomas, WHO grade 4), werestudied by immunohistochemistry using anti-pill monoclonal (TuJ1) and polyclonal antibodies. A monoclonal antibody to Ki-67 nuclear antigen (NC-MM1) was used as a marker For cell proliferation. Antibodies to glial fibrillaryacidic protein (GFAP) and BM89 synaptic vesicle antigen/synaptophysin wereused as glial and neuronal markers, respectively. Results.-The beta III immunoreactivity was significantly greater in high-grade astrocytomas (anaplastic astrocytomas and glioblastomas; median labeling index [MLI], 35%; interquartile range [IQR], 20%-47%) as compared with diffuse fibrillary astrocytomas (MLI, 4%; IQR, 0.2%-21%) (P < .0001) and wasrarely detectable in pilocytic astrocytomas (MLI, 0%; IQR, 0%-0.5%) (P < .0001 vs high-grade astrocytomas; P < .01 vs diffuse fibrillary astrocytomas). A highly significant, grade-dependent relationship was observed between <beta>III and Ki-67 labeling and malignancy, but this association was stronger for Ki-67 than for beta III (beta III, P < .006; Ki-67, P < .0001). There was co-localization of beta III and GFAP in neoplastic astrocytes, but no BM89 synaptic vesicle antigen/synaptophysin staining was detected. Conclusions.-In the context of astrocytic gliomas, beta III immunoreactivity is associated with an ascending gradient of malignancy and thus may be auseful ancillary diagnostic marker. However, the significance of pill-positive phenotypes in diffuse fibrillary astrocytomas with respect to prognostic and predictive value requires further evaluation. Under certain neoplastic conditions, pill expression is not neuron specific, calling For a cautious interpretation of pill-positive phenotypes in brain tumors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/01/20 alle ore 19:03:37